Androgen receptor‑mediated upregulation of quaking affects androgen receptor‑related prostate cancer development and anti‑androgen receptor therapy

Zhang,Keke; Yan,Fei; Lei,Xiaoying; Wei,Di; Lu,Huanyu; Zhu,Zheng; Xiang,An; Ye,Zichen; Wang,Li; Zheng,Wanxiang; Li,Xi'an; Yuan,Jiarui; Lu,Zifan; Yuan,Jianlin

doi:10.3892/mmr.2018.8882

Androgen receptor‑mediated upregulation of quaking affects androgen receptor‑related prostate cancer development and anti‑androgen receptor therapy

Authors:
- Keke Zhang
- Fei Yan
- Xiaoying Lei
- Di Wei
- Huanyu Lu
- Zheng Zhu
- An Xiang
- Zichen Ye
- Li Wang
- Wanxiang Zheng
- Xi'an Li
- Jiarui Yuan
- Zifan Lu
- Jianlin Yuan
View Affiliations

Affiliations: Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, State Key Laboratory of Cancer Biology, Department of Pharmacogenomics, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Biochemistry, University of Washington, Seattle, WA 98195‑5852, USA
Published online on: April 13, 2018 https://doi.org/10.3892/mmr.2018.8882
Pages: 8203-8211
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The androgen receptor (AR) has a crucial role in prostate cancer. RNA‑binding protein‑mediated post‑transcriptional regulation is important in the initiation and development of cancer. The present study attempted to elucidate the mutual association of AR and RNA‑binding protein quaking (QKI) in the development of prostate cancer. Dual‑luciferase reporter demonstrated that AR can positively regulate the expression of QKI in prostate cancer cell lines due to its effective transcription regulating function. In addition, QKI may increase expression of AR by heat shock protein 90, which is a coactivator of AR, and silencing QKI can increase the sensitive of Casodex, which is an antagonist of AR in castration‑resistant prostate cancer. This may be a new strategy for advanced prostate cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Babu Suresh S, Joladarashi D, Jeyabal P, Thandavarayan RA and Krishnamurthy P: RNA-stabilizing proteins as molecular targets in cardiovascular pathologies. Trends Cardiovasc Med. 25:676–683. 2015. View Article : Google Scholar : PubMed/NCBI
4	Feng Y and Bankston A: The star family member QKI and cell signaling. Adv Exp Med Biol. 693:25–36. 2010. View Article : Google Scholar : PubMed/NCBI
5	Bohnsack BL, Lai L, Northrop JL, Justice MJ and Hirschi KK: Visceral endoderm function is regulated by quaking and required for vascular development. Genesis. 44:93–104. 2006. View Article : Google Scholar : PubMed/NCBI
6	Zhao L, Ku L, Chen Y, Xia M, LoPresti P and Feng Y: QKI binds MAP1B mRNA and enhances MAP1B expression during oligodendrocyte development. Mol Biol Cell. 17:4179–4186. 2006. View Article : Google Scholar : PubMed/NCBI
7	Mulholland PJ, Fiegler H, Mazzanti C, Gorman P, Sasieni P, Adams J, Jones TA, Babbage JW, Vatcheva R, Ichimura K, et al: Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle. 5:783–791. 2006. View Article : Google Scholar : PubMed/NCBI
8	Yang G, Fu H, Zhang J, Lu X, Yu F, Jin L, Bai L, Huang B, Shen L, Feng Y, et al: RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology. 138(231–240): e1–e5. 2010.
9	Zong FY, Fu X, Wei WJ, Luo YG, Heiner M, Cao LJ, Fang Z, Fang R, Lu D, Ji H and Hui J: The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genet. 10:e10042892014. View Article : Google Scholar : PubMed/NCBI
10	Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA and Goodall GJ: The RNA binding protein quaking regulates formation of circRNAs. Cell. 160:1125–1134. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhao Y, Zhang G, Wei M, Lu X, Fu H, Feng F, Wang S, Lu W, Wu N, Lu Z and Yuan J: The tumor suppressing effects of QKI-5 in prostate cancer: A novel diagnostic and prognostic protein. Cancer Biol Ther. 15:108–118. 2014. View Article : Google Scholar : PubMed/NCBI
12	Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS and Plymate S: AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia. 15:1009–1017. 2013. View Article : Google Scholar : PubMed/NCBI
13	Garrido C, Paul C, Seigneuric R and Kampinga HH: The small heat shock proteins family: The long forgotten chaperones. Int J Biochem Cell Biol. 44:1588–1592. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kaul G and Thippeswamy H: Role of heat shock proteins in diseases and their therapeutic potential. Indian J Microbiol. 51:124–131. 2011. View Article : Google Scholar : PubMed/NCBI
15	Gao M, Geng XP and Xiang HP: HSP90 and SIRT3 expression in hepatocellular carcinoma and their effect on invasive capability of human hepatocellular carcinoma cells. Asian Pac J Trop Med. 8:305–308. 2015. View Article : Google Scholar : PubMed/NCBI
16	Liao X, Tang S, Thrasher JB, Griebling TL and Li B: Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther. 4:505–515. 2005. View Article : Google Scholar : PubMed/NCBI
17	Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD and Butler LM: Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget. 4:691–704. 2013. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Penel N: Splicing variant of androgen receptors (AR-V7): New paradigms. Bull Cancer. 103:711–713. 2016.(In French). View Article : Google Scholar : PubMed/NCBI
20	Fu X and Feng Y: QKI-5 suppresses cyclin D1 expression and proliferation of oral squamous cell carcinoma cells via MAPK signalling pathway. Int J Oral Maxillofac Surg. 44:562–567. 2015. View Article : Google Scholar : PubMed/NCBI
21	Yu F, Jin L, Yang G, Ji L, Wang F and Lu Z: Post-transcriptional repression of FOXO1 by QKI results in low levels of FOXO1 expression in breast cancer cells. Oncol Rep. 31:1459–1465. 2014. View Article : Google Scholar : PubMed/NCBI
22	Colabufo NA, Pagliarulo V, Berardi F, Contino M, Inglese C, Niso M, Ancona P, Albo G, Pagliarulo A and Perrone R: Bicalutamide failure in prostate cancer treatment: Involvement of multi drug resistance proteins. Eur J Pharmacol. 601:38–42. 2008. View Article : Google Scholar : PubMed/NCBI
23	Daniels G, Jha R, Shen Y, Logan SK and Lee P: Androgen receptor coactivators that inhibit prostate cancer growth. Am J Clin Exp Urol. 2:62–70. 2014.PubMed/NCBI